Advertisement

Pyrrolidones as Penetration Enhancers

  • R. Jayachandra Babu
  • Li Chen

Abstract

Pyrrolidines are not widely researched in the recent years as percutaneous penetration enhancers. The toxicity and skin irritancy of these enhancers may be the reason that these enhancers are not studied further. N-methyl-2-pyrrolidone (NMP) and its combination with other solvents such as isopropyl myristate (IPM) are researched in recent years for their synergistic enhancements in the percutaneous absorption of drugs. Pyrrolidones act as penetration enhancers due to their effects on the intercellular lipid bilayers in the stratum corneum. These enhancers penetrate into this region in such amounts that they alter the solubilizing ability of this site, thereby promoting drug partition into the skin. NMP is also known to form hydrogen bonds with basic drugs and cotransport the penetrant across the skin.

Keywords

Stratum Corneum Skin Permeation Percutaneous Absorption Penetration Enhancer Hairless Mouse Skin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akhter SA, Barry BW (1985) Absorption through human skin of ibuprofen and flurbiprofen; effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone. J Pharm Pharmacol 37(1):27–37CrossRefPubMedGoogle Scholar
  2. Akrill P, Cocker J, Dixon S (2002) Dermal exposure to aqueous solutions of N-methyl pyrrolidone. Toxicol Lett 134:265–269CrossRefPubMedGoogle Scholar
  3. Ansell JM, Fowler JA (1988) The acute oral toxicity and primary ocular and dermal irritation of selected N-alkyl-2-pyrrolidones. Food Chem Toxicol 26:475–479CrossRefPubMedGoogle Scholar
  4. Aungst BJ, Rogers NJ, Shefter E (1986) Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm 33:225–234CrossRefGoogle Scholar
  5. Babu RJ, Pandit JK (2005a) Effect of penetration enhancers on the release and skin permeation of bupranolol from reservoir-type transdermal delivery systems. Int J Pharm 288(2):325–334CrossRefPubMedGoogle Scholar
  6. Babu RJ, Pandit JK (2005b) Effect of penetration enhancers on the transdermal delivery of bupranolol through rat skin. Drug Deliv 12(3):165–169CrossRefPubMedGoogle Scholar
  7. Bachhav YG, Date AA, Patravale VB (2006) Exploring the potential of N-methyl pyrrolidone as a cosurfactant in the microemulsion systems. Int J Pharm 326:186–189CrossRefPubMedGoogle Scholar
  8. Barry BW (1983) Properties that influence percutaneous absorption. In: Dermatological formulations percutaneous absorption. Marcel Dekker, New York, pp 127–233Google Scholar
  9. Barry BW (1987) Mode of action of penetration enhancers in human skin. J Control Release 6(1):85–97CrossRefGoogle Scholar
  10. Barry BW, Bennett SL (1987) Effect of penetration enhancers on the permeation of mannitol, hydrocortisone and progesterone through human skin. J Pharm Pharmacol 39:535–546CrossRefPubMedGoogle Scholar
  11. Barry BW, Williams AC (1995) Permeation enhancement through skin. In: Swarbrick J, Boylon JC (eds) Encyclopedia of pharmaceutical technology, vol 12. Marcel Dekker Inc, New York, pp 449–493Google Scholar
  12. Barry BW, Southwell D, Woodford R (1984) Optimization of bioavailability of topical steroids: penetration enhancers under occlusion. J Invest Dermatol 82:49–52CrossRefPubMedGoogle Scholar
  13. Becci PJ, Knickerbocker MJ, Reagan EL, Parent RA, Llewellyn WB (1982) Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats. Fundam Appl Toxicol 2:73–76CrossRefPubMedGoogle Scholar
  14. Bennett SL, Barry BW, Woodford R (1984) Optimization of bioavailability of topical steroids: non-occluded penetration enhancers under thermodynamic control. J Pharm Pharmacol 37:298–304CrossRefGoogle Scholar
  15. Bhatia KS, Singh J (1997) Percutaneous absorption of LHRH through porcine skin: effect of N-Methyl-2-pyrrolidone and isopropyl myristate. Drug Dev Ind Pharm 23:1111–1114CrossRefGoogle Scholar
  16. Bonina F, Santagati NA, Puglia C (2003) Ketoprofen 1-alkylazacycloalkan-2-one esters as dermal prodrugs: in vivo and in vitro evaluations. Drug Dev Ind Pharm 29(2):181–190CrossRefPubMedGoogle Scholar
  17. Chow ST, Ng TL (1983) The biodegradation of N-methyl-2-pyrrolidone in water by sewage bacteria. Water Res 17(1):117–118CrossRefGoogle Scholar
  18. Cross SE, Pugh WJ, Hadgraft J, Roberts MS (2001) Probing the effect of vehicles on topical delivery: understanding the basic relationship between solvent and solute penetration using silicone membranes. Pharm Res 18:999–1005CrossRefPubMedGoogle Scholar
  19. E.I. du Pont de Nemours and Company, Wilmington, DE (1976) Primary skin irritation and sensitization test on guinea pigs. Haskell Laboratory Report No. 307–776Google Scholar
  20. El-Hinnawi MA, Najib NM (1987) Ibuprofen-polyvinylpyrrolidone dispersions. Proton nuclear magnetic resonance and infrared studies. Int J Pharm 37:175–177CrossRefGoogle Scholar
  21. Godavarthy SS, Yerramsetty KM, Rachakonda VK, Neely BJ, Madihally SV, Robinson RL Jr, Gasem KA (2009) Design of improved permeation enhancers for transdermal drug delivery. J Pharm Sci 98:4085–4099CrossRefPubMedGoogle Scholar
  22. Godwin DA, Michniak BB, Player MR, Sowell JW (1997) Transdermal and dermal enhancing activity of pyrrolidinones in hairless mouse skin. Int J Pharm 155:241–250CrossRefGoogle Scholar
  23. Hoelgaard A, Mollgaard B, Baker E (1988) Effect of N-methyl pyrrolidone and polar lipids on percutaneous drug transport. Int J Pharm 43:233–240Google Scholar
  24. Jouyban A, Fakhree MAA, Shayanfar A (2010) Review of pharmaceutical applications of N-ethyl-2-pyrrolidone. J Pharm Sci 13(4):524–535Google Scholar
  25. Kakubari I, Nakamura N, Takayasu T, Yamauchi H, Takayama S, Takayama K (2006) Effects of solvents on skin permeation of formoterol fumarate. Biol Pharm Bull 29(1):146–149CrossRefPubMedGoogle Scholar
  26. Karande P, Mitragotri S (2009) Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim Biophys Acta 1788(11):2362–2373CrossRefPubMedGoogle Scholar
  27. Kikwai L, Babu RJ, Prado R, Kolot A, Armstrong CA, Ansel JC et al (2005) In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS PharmSciTech 6(4):E565–E572PubMedCentralCrossRefPubMedGoogle Scholar
  28. Kim YH, Ghanem AH, Mahmoud H, Higuchi WI (1992) Short chain alkanols as transport enhancers for lipophilic and polar/ionic permeants in hairless mouse skin: mechanism (s) of action. Int J Pharm 80(1):17–31CrossRefGoogle Scholar
  29. Koizumi A, Fujii M, Kondoh M, Watanabe Y (2004) Effect of N-methyl-2-pyrrolidone on skin permeation of estradiol. Eur J Pharm Biopharm 57:473–478CrossRefPubMedGoogle Scholar
  30. Lambert WJ, Kudla RJ, Holland JM, Curry JT (1993) A biodegradable transdermal penetration enhancer based on N-(2-hydroxyethyl)-2-pyrrolidone. I. Synthesis and characterization. Int J Pharm 95:181–192CrossRefGoogle Scholar
  31. Lee PJ, Langer R, Shastri VP (2003) Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs. Pharm Res 20:264–269CrossRefPubMedGoogle Scholar
  32. Lee PJ, Langer R, Shastri VP (2005) Role of n-methyl pyrrolidone in the enhancement of aqueous phase transdermal transport. J Pharm Sci 94:912–917CrossRefPubMedGoogle Scholar
  33. Lee PJ, Ahmad N, Langer R, Mitragotri S, Prasad Shastri V (2006) Evaluation of chemical enhancers in the transdermal delivery of lidocaine. Int J Pharm 308:33–39CrossRefPubMedGoogle Scholar
  34. Ma X, Fang L, Guo JP, Zhao N, He ZG (2010) Effect of counter-ions and penetration enhancers on the skin permeation of flurbiprofen. J Pharm Sci 99:1826–1837PubMedGoogle Scholar
  35. Mollgaard B, Hoelgaard A, Baker E (1988) Vehicle effects on topical drug delivery: effect of N-methyl pyrrolidone, polar lipids and Azone on percutaneous drug transport. Proc Int Symp Controlled Rel Bioact Mater 15:209Google Scholar
  36. Nair A, Reddy C, Jacob S (2009) Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis. Skin Res Technol 15:187–194CrossRefPubMedGoogle Scholar
  37. Naito SI, Nakamori S, Awataguchi M, Nakayama T, Tominaga H (1985) Observations on and pharmacokinetic discussion of percutaneous absorption of mefenamic acid. Int J Pharm 24:127–147CrossRefGoogle Scholar
  38. Ogiso T, Hata T, Iwaki M, Tanino T (2001) Transdermal absorption of bupranolol in rabbit skin in vitro and in vivo. Biol Pharm Bull 24:588–591CrossRefPubMedGoogle Scholar
  39. Payan JP, Boudry I, Beydon D, Fabry JP, Grandclaude MC, Ferrari E et al (2003) Toxicokinetics and metabolism of N-[(14)C]N-methyl-2-pyrrolidone in male Sprague-Dawley rats: in vivo and in vitro percutaneous absorption. Drug Metab Dispos 31:659–669CrossRefPubMedGoogle Scholar
  40. Rachakonda VK, Yerramsetty KM, Madihally SV, Robinson RL, Gasem KA (2008) Screening of chemical penetration enhancers for transdermal drug delivery using electrical resistance of skin. Pharm Res 25:2697–2704CrossRefPubMedGoogle Scholar
  41. Santos GC, Baker RW (1993) Transdermal enhancer patent literature. J Control ReIease 25:1–20CrossRefGoogle Scholar
  42. Sasaki H, Kojima M, Mori Y, Nakamura J, Shibasakl J (1988) Enhancing effects of pyrrolidone derivatives on transdermal drug delivery. I. Int J Pharm 44:15–24CrossRefGoogle Scholar
  43. Sasaki H, Kojima M, Nakamura J, Shlhasaki J (1990a) Enhancing effect of pyrrolidone derivatives on the transdermal penetration of sulfaguanidine, aminopyrine and sudan Ill. J Pharmacobiodyn 13:200–205CrossRefPubMedGoogle Scholar
  44. Sasaki H, Kojima M, Morl Y, Nakamura J, Shlbasakl J (1990b) Enhancing effect pyrrolidone derivatives on transdermal drug delivery. II. Effect of application concentration and pretreatment of enhancer. Int J Pharm 60:177–183CrossRefGoogle Scholar
  45. Sasaki H, Kojima M, Nakamura J, Shlbasaki J (1990c) Enhancing effect of pyrrolidone derivatives on transdermal penetration of phenolsulfonphthalein and indomethacin from aqueous vehicle. Chem Pharm Bull 38:797–799CrossRefPubMedGoogle Scholar
  46. Sasaki H, Kojima M, Nakamura J, Shibasaki J (1990d) Enhancing effect of combining two pyrrolidone vehicles on transdermal drug delivery. J Pharm Pharmacol 42:196–199CrossRefPubMedGoogle Scholar
  47. Sasaki H, Kishikawa M, Nakamura J, Shibasaki J (1990e) Effect of pyrrolidone derivatives on lipid membrane and protein conformation as transdermal penetration enhancer. J Pharmacobiodyn 13:468–474CrossRefPubMedGoogle Scholar
  48. Sasaki H, Kojima M, Morl Y, Nakamura J, ShlbaSaki J (1991) Enhancing effect 0 pyrrolidone derivatives on transdermal penetration of 5-fluorouracil, triamcinolone acetonide indomethacin, and flurbiprofen. J Pharm Sci 80:533–538CrossRefPubMedGoogle Scholar
  49. Sasaki H, Nishida K, Nakamura J (1995) Pyrrolidones as penetration enhancers. In: Maibach HI, Smith EW (eds) Percutaneous penetration enhancers. CRC Press, Boca Raton, pp 211–220Google Scholar
  50. Shah HS, Tojo K, Chien YW (1992) Enhancement of in vitro skin permeation of verapamil. Drug Dev Ind Pharm 18:1461–1476CrossRefGoogle Scholar
  51. Shishu, Aggarwal N (2006) Preparation of hydrogels of griseofulvin for dermal application. Int J Pharm 326:20–24CrossRefPubMedGoogle Scholar
  52. Southwell D, Barry BW (1983) Penetration enhancers for human skin: mode of action of 2-pyrrolidone and dimethylformamide on partition and diffusion of model compounds, water, n-alkanols and caffeine. J Invest Dermatol 80:507–514CrossRefPubMedGoogle Scholar
  53. Southwell D, Barry BW (1984) Penetration enhancement in human skin: effect of 2-pyrrolidone, dimethylformamide and increased hydration on finite dose permeation of aspirin and caffeine. Int J Pharm 22:291–298CrossRefGoogle Scholar
  54. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21(2):201–230CrossRefPubMedGoogle Scholar
  55. Suwanpidokkul N, Thongnopnua P, Umprayn K (2004) Transdermal Delivery of Zidovudine (AZT): the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech 5(3):1–8CrossRefGoogle Scholar
  56. Uch AS, Hesse U, Dressman JB (1999) Use of 1-methyl-pyrrolidone as a solubilizing agent for determining the uptake of poorly soluble drugs. Pharm Res 16:968–971CrossRefPubMedGoogle Scholar
  57. Walters KA (1987) Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft J, Guy RH (eds) Transdermal drug delivery, developmental issues and research initiatives. Marcel Dekker Inc, New York, pp 197–246Google Scholar
  58. Walters KA, Roberts MS (2002) The structure and function of skin. In: Walters KA (ed) Dermatological and topical formulations. Marcel and Dekker Inc, New York, pp 1–42CrossRefGoogle Scholar
  59. Warner KS, Li SK, Higuchi WI (2001) Influences of alkyl group chain length and polar head group on chemical skin permeation enhancement. J Pharm Sci 90:1143–1153CrossRefPubMedGoogle Scholar
  60. Williams AC, Barry BW (2012) Penetration enhancers. Adv Drug Deliv Rev 64:128–137CrossRefGoogle Scholar
  61. Yoneto K, Ghanem AH, Higuchi WI, Peck KD, Li SK (1995) Mechanistic studies of the 1-alkyl-2-pyrrolidones as skin permeation enhancers. J Pharm Sci 84:312–317CrossRefPubMedGoogle Scholar
  62. Zheng WW, Zhao L, Wei YM, Ye Y, Xiao SH (2010) Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull 58(8):1015–1019CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Drug Discovery and DevelopmentHarrison School of Pharmacy, Auburn UniversityAuburnUSA
  2. 2.Department of Drug Discovery and DevelopmentHarrison School of Pharmacy, Auburn UniversityAuburnUSA

Personalised recommendations